DK3010537T3 - Fremgangsmåde til forebyggelse af aggregation af viruskomponenter - Google Patents

Fremgangsmåde til forebyggelse af aggregation af viruskomponenter Download PDF

Info

Publication number
DK3010537T3
DK3010537T3 DK14734942.7T DK14734942T DK3010537T3 DK 3010537 T3 DK3010537 T3 DK 3010537T3 DK 14734942 T DK14734942 T DK 14734942T DK 3010537 T3 DK3010537 T3 DK 3010537T3
Authority
DK
Denmark
Prior art keywords
basic amino
hrv
amino acid
virus
arginine
Prior art date
Application number
DK14734942.7T
Other languages
English (en)
Inventor
't Oever Arend Gesinus Van
Wilfridus Adrianus Maria Bakker
Yvonne Elisabeth Thomassen
Original Assignee
De Staat Der Nederlanden Vert Door De Mini Van Vws Mini Van Volksgezondheit Welzijn En Sport
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Staat Der Nederlanden Vert Door De Mini Van Vws Mini Van Volksgezondheit Welzijn En Sport filed Critical De Staat Der Nederlanden Vert Door De Mini Van Vws Mini Van Volksgezondheit Welzijn En Sport
Application granted granted Critical
Publication of DK3010537T3 publication Critical patent/DK3010537T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32663—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (15)

1. Fremgangsmåde til fremstilling afen sammensætning omfattende enterovi-ruspartikler, hvor fremgangsmåden omfatter trinnene: a) fremstilling af et medium indeholdende enteroviruspartiklerne; b) oprensning af enteroviruspartiklerne fra mediet, hvor en basisk aminosyre eller et derivat deraf under mindst en del af oprensningen er til stede i en slut-koncentration på mindst 1 mM og er tilstrækkelig til at forhindre eller reducere aggregation af enteroviruspartiklerne; og c) inaktivering af enteroviruspartiklerne; hvor den basiske aminosyre eller derivatet deraf er udvalgt fra gruppen bestående af: arginin, lysin, histidin, arginin-HCI, lysin-HCI, histidin-HCI, agmatin, L-argininethylesterdihydrochlorid, tranexamsyre, DL-5-hydroxylysinhydrochlo-rid, L-lysinmethylesterdihydrochlorid, 3-methyl-L-histidin, salte deraf og kombinationer deraf.
2. Fremgangsmåde ifølge krav 1, yderligere omfattende et trin d), hvor enteroviruspartiklerne formuleres.
3. Fremgangsmåde ifølge krav 1 eller 2, hvor den basiske aminosyre eller derivatet deraf er til stede i en slutkoncentration på mindst 1 mM og er tilstrækkelig til at forhindre eller reducere aggregation af enteroviruspartiklerne under mindst en del af trin c).
4. Fremgangsmåde ifølge krav 3, hvor den basiske aminosyre eller derivatet deraf også under trin d) er til stede i en slutkoncentration på mindst 1 mM og er tilstrækkelig til at forhindre eller reducere aggregation af enteroviruspartiklerne.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 - 4, hvor koncentrationen af den basiske aminosyre eller derivatet deraf er mindst 1 mM og tilstrækkelig til at forhindre eller reducere aggregation af enteroviruspartiklerne og opretholdes under hele varigheden af mindst et blandt trin b), c) og d).
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1 - 5, hvor slutkon-centrationen af den basiske aminosyre eller derivatet deraf er mindst 5 mM, 10 mM, 25 mM, 50 mM eller 100 mM og er tilstrækkelig til at forhindre eller reducere aggregation af enteroviruspartiklerne.
7. Fremgangsmåde ifølge et hvilket som helst af kravene 1 - 6, hvor enteroviruspartiklerne er viruslignende partikler af en enterovirus.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1 - 7, hvor enteroviruspartiklerne er af en Enterovirus udvalgt fra gruppen bestående af poliovira, coxsackie A-vira, coxsackie B-vira, echovira, rhinovira og enterovirus 68, 69, 70, 71 og 73 .
9. Fremgangsmåde ifølge krav 8, hvor enteroviruspartiklerne omfatter poliovira af serotyperne 1,2 og 3.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 9, hvor sammensætningen omfattende enteroviruspartikler er en vaccine.
11. Fremgangsmåde ifølge krav 10, hvor vaccinen er en inaktiveret poliovaccine (IPV).
12. Anvendelse afen basisk aminosyre eller et derivat deraf til forhindring eller reduktion af aggregation af enteroviruspartikler under oprensning af enteroviruspartikler fra et medium, hvor en basisk aminosyre eller et derivat deraf under mindst en del af oprensningen er til stede i en slutkoncentration på mindst 1 mM og er tilstrækkelig til at forhindre eller reducere aggregation af enteroviruspartiklerne, og hvor den basiske aminosyre eller derivatet deraf er udvalgt fra gruppen bestående af: arginin, lysin, histidin, arginin-HCI, lysin-HCI, hi-stidin-HCI, agmatin, L-argininethylesterdihydrochlorid, tranexamsyre, DL-5-hy-droxylysinhydrochlorid, L-lysinmethylesterdihydrochlorid, 3-methyl-L-histidin, salte deraf og kombinationer deraf.
13. Anvendelse ifølge krav 12, hvor enteroviruspartiklerne er af en Enterovirus udvalgt fra gruppen bestående af poliovira, coxsackie A-vira, coxsackie B-vira, echovira, rhinovira og enterovirus 68, 69, 70, 71 og 73.
14. Fremgangsmåde ifølge krav 13, hvor enteroviruspartiklerne er poliovira af mindst en af serotyperne 1, 2 og 3.
15. Anvendelse ifølge krav 13, hvor enteroviruspartiklerne er en inaktiveret poliovaccine (IPV).
DK14734942.7T 2013-06-17 2014-06-17 Fremgangsmåde til forebyggelse af aggregation af viruskomponenter DK3010537T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13172263 2013-06-17
PCT/NL2014/050395 WO2014204303A2 (en) 2013-06-17 2014-06-17 Methods for the prevention of aggregation of viral components

Publications (1)

Publication Number Publication Date
DK3010537T3 true DK3010537T3 (da) 2018-09-24

Family

ID=48625913

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14734942.7T DK3010537T3 (da) 2013-06-17 2014-06-17 Fremgangsmåde til forebyggelse af aggregation af viruskomponenter

Country Status (16)

Country Link
US (1) US10080793B2 (da)
EP (1) EP3010537B1 (da)
KR (1) KR102219672B1 (da)
CN (1) CN105517568B (da)
BR (1) BR112015031541A2 (da)
DK (1) DK3010537T3 (da)
ES (1) ES2689150T3 (da)
HK (1) HK1223845A1 (da)
HR (1) HRP20181606T1 (da)
HU (1) HUE040108T2 (da)
LT (1) LT3010537T (da)
PL (1) PL3010537T3 (da)
PT (1) PT3010537T (da)
RS (1) RS57864B1 (da)
SI (1) SI3010537T1 (da)
WO (1) WO2014204303A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11160857B2 (en) 2015-06-15 2021-11-02 Emory University Multivalent enterovirus vaccine compositions and uses related thereto
US11911457B2 (en) * 2018-02-07 2024-02-27 Bharat Biotech International Limited Process for enterovirus purification and inactivation and vaccine compositions obtained thereof
CA3095478A1 (en) * 2018-03-30 2019-10-03 Biological Mimetics, Inc. Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation
CN108578399B (zh) * 2018-07-10 2020-01-07 湖北工业大学 氨基酸酯化合物在制备抗cvb3病毒药物中的应用
CA3152838A1 (en) * 2019-08-30 2021-03-04 Kashiv Biosciences, Llc Novel formulation of highly concentrated pharmacologically active antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0487632T3 (da) * 1989-08-15 1998-05-25 Massachusetts Inst Technology Stabiliserede vaccinesammensætninger
SI1699919T1 (sl) 2003-12-24 2017-07-31 De Staat der Nederlanden, Vertegenwoordigd Door de Minister Van Volksgezondheid, Welzijn Respiratorni sincicijski virus z genomsko pomanjkljivostjo komplementarno v trans
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
CN101018858A (zh) * 2004-06-01 2007-08-15 建新公司 防止aav载体聚集的组合物和方法
EP3290513B1 (en) * 2004-06-01 2022-09-07 Genzyme Corporation Compositions and methods to prevent aav vector aggregation
WO2007007344A1 (en) * 2004-08-27 2007-01-18 Panacea Biotec Ltd. Inactivated poliomyelitis vaccine derived from sabin strain of polio virus
KR101679812B1 (ko) 2007-09-14 2016-11-28 사노피 파스테르 바이오로직스, 엘엘씨 클로스트리듐 디피실리 톡소이드 ａ 및 ｂ를 포함하는 약학적 조성물
PT2454364E (pt) 2009-07-16 2014-07-04 Crucell Holland Bv Produção de poliovírus com elevados títulos para produção de vacina
ES2822199T3 (es) 2011-04-29 2021-04-29 Oncolytics Biotech Inc Métodos de purificación de virus usando cromatografía por permeación en gel

Also Published As

Publication number Publication date
US10080793B2 (en) 2018-09-25
HK1223845A1 (zh) 2017-08-11
EP3010537A2 (en) 2016-04-27
CN105517568A (zh) 2016-04-20
CN105517568B (zh) 2020-07-07
HUE040108T2 (hu) 2019-02-28
KR20160019477A (ko) 2016-02-19
EP3010537B1 (en) 2018-07-11
HRP20181606T1 (hr) 2018-11-30
BR112015031541A2 (pt) 2017-07-25
SI3010537T1 (sl) 2018-09-28
KR102219672B1 (ko) 2021-02-25
LT3010537T (lt) 2018-10-25
PL3010537T3 (pl) 2019-03-29
ES2689150T3 (es) 2018-11-08
WO2014204303A2 (en) 2014-12-24
WO2014204303A3 (en) 2015-10-08
US20160184423A1 (en) 2016-06-30
RS57864B1 (sr) 2018-12-31
PT3010537T (pt) 2019-12-03

Similar Documents

Publication Publication Date Title
US11466257B2 (en) Cell-derived viral vaccines with low levels of residual cell DNA
US11207397B2 (en) Virus purification
JP5845178B2 (ja) ワクチン生産のためのポリオウイルスの高力価での生産
Chang et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development
ES2488818T3 (es) Método para la producción a gran escala de virus
DK3010537T3 (da) Fremgangsmåde til forebyggelse af aggregation af viruskomponenter
JP5960120B2 (ja) ウイルス粒子の安定化
PT1427815E (pt) Métodos para a produção industrial de vacinas
JP2014500008A (ja) インフルエンザウイルス及びワクチンシードの製造を改善する方法
WO2008073490A1 (en) Purification of influenza viral antigens
US10238730B2 (en) Cold-adapted-viral-attenuation (CAVA) and novel attenuated poliovirus strains
EA010057B1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
CA2691629C (en) Adaptation of pitman moore strain of rabies virus to primary chick embryo fibroblast cell cultures
KR20110092280A (ko) ｐＨ에 안정한 외피보유 바이러스의 생산 방법
Jagannathan et al. Kinetics analysis of beta-propiolactone with tangential flow filtration (TFF)
TWI747866B (zh) 藉由去脂質化使病原體不活化
JP2023511823A (ja) Ａ型肝炎ウイルスの製造方法及び前記方法により製造されたａ型肝炎ウイルス
CA3142740A1 (en) Influenza virus backbone
WO2020075197A1 (en) Inactivated poliomyelitis vaccine composition
BRPI0618094B1 (pt) Método para preparar um produto de cultura de célula